Novartis AG ADR (NVS): Price and Financial Metrics

NVS POWR Grades

• NVS scores best on the Stability dimension, with a Stability rank ahead of 98.82% of US stocks.
• NVS's strongest trending metric is Growth; it's been moving down over the last 177 days.
• NVS's current lowest rank is in the Growth metric (where it is better than 17.08% of US stocks).

NVS Stock Summary

• With a market capitalization of $182,498,339,808, NOVARTIS AG has a greater market value than 99.05% of US stocks.
• In terms of volatility of its share price, NVS is more volatile than just 8.34% of stocks we're observing.
• NOVARTIS AG's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 11.3%, greater than the shareholder yield of 86.56% of stocks in our set.
• Stocks with similar financial metrics, market capitalization, and price volatility to NOVARTIS AG are AZN, BMY, RTX, TXN, and NFLX.
• Visit NVS's SEC page to see the company's official filings. To visit the company's web site, go to www.novartis.com.

NVS Valuation Summary

• In comparison to the median Healthcare stock, NVS's price/sales ratio is 27.45% lower, now standing at 3.7.
• NVS's price/sales ratio has moved down 1.8 over the prior 243 months.

Below are key valuation metrics over time for NVS.

NVS Growth Metrics

The 5 year cash and equivalents growth rate now stands at -45.03%.
• The 3 year revenue growth rate now stands at 2.52%.
• Its year over year cash and equivalents growth rate is now at 264.43%.

NVS's revenue has moved up $2,852,000,000 over the prior 67 months.

The table below shows NVS's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	52,263	14,009	21,797
2022-06-30	52,788	14,213	22,982
2022-03-31	52,997	14,590	24,184
2021-12-31	52,877	15,071	24,021
2021-09-30	52,385	15,192	9,807
2021-06-30	51,556	13,423	8,984

NVS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• NVS has a Quality Grade of B, ranking ahead of 86.01% of graded US stocks.
• NVS's asset turnover comes in at 0.42 -- ranking 108th of 682 Pharmaceutical Products stocks.
• GHSI, KALA, and ADAP are the stocks whose asset turnover ratios are most correlated with NVS.

The table below shows NVS's key quality metrics over time.